Author:
Aboagye E O,Luthra S K,Brady F,Poole K,Anderson H,Jones T,Boobis A,Burtles S S,Price P
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. ARSAC (1998) Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Administration of radioactive substances advisory committee. pp 1–69. Didcot, UK
2. Begent RHJ, Chester KA, Connors T, Crowther D, Fox B, Griffiths E, Hince TA, Ledermann JA, McVie JG, Minor P, Secher DS, Schwartsmann G, Thorpe R, Wilbin C, Zwierzina H (1993) Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials. Eur J Cancer 29A: 1907–1910
3. Begent RHJ, Searle F, Keep PA, Baldwin RW, Connors TA, Hince TA, Smith JWG, Griffiths E, Coombes C, Kemshead JT (1986) Cancer Research Campaign operation manual for control of production, preclinical toxicology and phase 1 trials of anti-tumour antibodies and drug antibody conjugates. Br J Cancer 54: 557–568
4. Burtles SS, Newell DR, Henrar REC, Connors TA (1995) Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur J Cancer 31A: 408–410
5. CRC/EORTC (1999) Preclinical toxicology of anti-cancer agents within the EORTC and CRC London: CRC
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献